Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of H021 in Healthy Participants
NCT06627556Phase 1Recruiting
- Sponsor
- Carephar
- Start
- Sep 2024
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of H021 in ulcerative colitis (UC) (10 arms), sponsored by Carephar. Primary endpoint: Number of Participants with Adverse Events up to 14 days. Started Sep 2024; status: recruiting.
02
Drugs
H021
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06627556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06627556.